Sitagliptin (Januvia) is a drug used in the treatment of:

Sitagliptin does not have any therapeutic effects on schizophrenia, a mental health disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. Treatment for schizophrenia typically involves antipsychotic medications, which are entirely different from the mechanisms of action of sitagliptin.

Parkinson's disease is a neurodegenerative disorder that affects movement. The management of Parkinson's symptoms often includes dopaminergic medications like levodopa, which contrast sharply with sitagliptin's glucose-lowering properties. Thus, sitagliptin is not indicated for the treatment of this condition.

Type 1 diabetes is an autoimmune condition that results in the destruction of insulin-producing beta cells in the pancreas. Treatment typically requires insulin replacement therapy, as sitagliptin is ineffective and not approved for managing type 1 diabetes, which requires a different approach to treatment.